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Abstract:  18 
Bluetongue (BT) is a severe and economically important disease of ruminants that is 19 
widely distributed around the world, caused by the bluetongue virus (BTV). More 20 
than 28 different BTV serotypes have been identified in serum neutralisation tests 21 
(SNT), which along with geographic variants (topotypes) within each serotype, reflect 22 
differences in BTV outer-capsid protein VP2. VP2 is the primary target for neutralis- 23 
ing antibodies, although the basis for cross-reactions and serological variations be- 24 
tween and within BTV serotypes is poorly understood. Recombinant BTV VP2 pro- 25 
teins (rVP2) were expressed in Nicotiana benthamiana, based on sequence data for 26 
isolates of thirteen BTV serotypes (primarily from Europe), including three ‘novel’ 27 
serotypes (BTV-25, -26 and -27) and alternative topotypes of four serotypes. Cross- 28 
reactions within and between these viruses were explored using rabbit anti-rVP2 sera 29 
and post BTV-infection sheep reference-antisera, in I-ELISA (with rVP2 target anti- 30 
gens) and SNT (with reference strains of BTV-1 to -24, -26 and -27). Strong reactions 31 
were generally detected with homologous rVP2 proteins or virus strains/serotypes. 32 
The sheep antisera were largely serotype-specific in SNT, but more cross-reactive by 33 
ELISA. Rabbit antisera were more cross-reactive in SNT, and showed widespread, 34 
high titre cross-reactions against homologous and heterologous rVP2 proteins in 35 
ELISA. Results were analysed and visualised by antigenic cartography, showing 36 
closer relationships in some but not all cases between VP2 topotypes within the same 37 
serotype, and between serotypes belonging to the same ‘VP2 nucleotype’.     38 
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 1. Introduction 44 
Bluetongue virus is the ‘type’ species and most intensively studied member of the genus 45 
Orbivirus, within the family Reoviridae, order Reovirales [1-4]. BTV can infect most rumi- 46 
nants, as well as camelids and some large carnivores [5], causing ‘bluetongue’ (BT), an 47 
economically important, clinically severe and sometimes fatal disease primarily of 48 
sheep, cattle and some deer species [5, 6]. At least 28 BTV serotypes have been identified 49 
in serum neutralisation tests (SNT), most of which are transmitted by adult females of 50 
vector-competent biting-midge species (Culicoides spp.) [6-8]. However, some of the most 51 
recently discovered BTV serotypes [9-13] do not appear to infect midges and are thought 52 
to be transmitted by direct contact between individual hosts [7, 14].  53 
In recent decades, bluetongue has spread into new habitats, including 12 serotypes de- 54 
tected in Europe since 1998. This movement has been linked to increased human travel 55 
and trade, and the effects of climate change on vector-insect activity and distribution in 56 
the region [15-17].   57 
BTV is usually regarded as having a non-enveloped icosahedral virus particle, although 58 
membrane enveloped virus particles (MEVP) have also been observed by electron-mi- 59 
croscopy [1-4]. The BTV capsid is approximately 80nm in diameter, comprising three 60 
concentric layers of proteins. The innermost ‘sub-core’ layer, which is composed of vi- 61 
rus-protein 3 (VP3), encoded by the third largest of the ten BTV genome segments (Seg- 62 
3), is surrounded by an intermediate ‘core-surface’ layer of VP7 (encoded by Seg-7), with 63 
an ‘outer-capsid’ composed of VP2 and VP5 (encoded by Seg-2 and Seg-6 respectively) 64 
[1-3]. The BTV core contains ten linear double-stranded (ds) RNA genome segments, 65 
associated with multiple transcriptase complexes, composed of minor proteins VP1, VP4 66 
and VP6 (encoded by Seg-1, -4 and -9) [1, 2]. BTV also encodes at least 5 distinct non- 67 
structural proteins [4, 18]. The outer-most BTV capsid protein, VP2, displays hemagglu- 68 
tination activity and is responsible for cell attachment during the early stages of infection 69 
[19, 20].  70 
Interaction of VP2 with the antibodies generated by infected mammalian hosts, can block 71 
cell binding, neutralising BTV infectivity [21 24]. The specificity of these neutralising an- 72 
tibodies (nAbs) (as detected in SNT) is controlled by variations in the amino acid (aa) 73 
sequence of VP2 [24 27]. Phylogenetic analyses of Seg 2 (which encodes VP2) shows a 74 
strong correlation with the serological identity of BTV isolates, with between 29-59% 75 
nucleotide sequence variation between different serotypes [24-27]. These phylogenetic 76 
analyses have also identified closer relationships between Seg-2 of some BTV serotypes, 77 
placing them in 11 larger groups (‘Seg-2 nucleotypes’ A–K) [20, 24, 27]. The nAbs target- 78 
ing BTV VP2 are protective and consequently VP2 is a primary target for vaccine devel- 79 
opment. Seg-2 has also become a target for the RT-PCR assays that are now widely used 80 
for rapid diagnosis, detection and identification of different BTV serotypes in epidemi- 81 
ological and ‘vaccine matching’ studies, largely replacing the slower and less sensitive 82 
SNT [20, 30-33].    83 
However, up to 32% sequence variations can exist in Seg-2, with variations in VP2 aa 84 
sequence up to 16%, between viruses within the same BTV serotype. These intra-sero- 85 
type differences often reflect different geographical origins, grouping isolates of the 86 
same serotype from south-east Asia, India, China and Australia into a major eastern Seg- 87 
2/VP2 ‘topotype’, while viruses from Africa, North and South America form a major 88 
western Seg-2/VP2 ‘topotype’. However, recent intercontinental movements and spread 89 
of BTV strains are increasingly blurring these geographic separations.[20, 28, 29].  90 
In addition to the strong serotype-specific reactions, low-level, variable, or one-way 91 
cross-serotype reactions have also been detected in cross-protection studies in sheep and 92 
in tissue culture based SNT, that show at least partial correlation with the ‘nucleotype 93 
grouping’ of BTV Seg-2 [25, 27, 34, 35]. However, nAbs are only a subset of the antibodies 94 
generated against VP2 and the other structural and non-structural proteins of the virus, 95 
during infection of mammalian hosts. A significant proportion of the VP2-binding Abs 96 
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(VP2-bAbs) are non-neutralising and may be both non-protective and more cross-reac- 97 
tive between serotypes [36, 37].   98 
In order to explore the potential for serotype cross-reactive antibodies and vaccines tar- 99 
geting VP2, we have expressed rVP2s from 17 BTV strains in Nicotiana benthamiana [23, 100 
38, 39]. These include proteins from isolates of 11 serotypes detected in Europe and the 101 
Mediterranean region since 1998 [15, 40-42], as well as from different topotypes of four 102 
serotypes and isolates of novel serotypes BTV-25, -26 and -27) (Table 1). Ten of these 103 
rVP2 proteins were used to generate antisera in rabbits and the specificity of VP2-bAbs 104 
was analysed by indirect (I)-ELISA. The results were visualised by antigenic-cartog- 105 
raphy and compared to data generated in using reference antisera from sheep previously 106 
infected with strains of the different BTV serotypes.  The subset of VP2 specific neutral- 107 
ising antibodies (nAbs) was also evaluated in SNT against the reference strains of BTV 108 
serotypes -1 to -24, -26 and -27.   109 
 110 
2. Materials and Methods 111 
2.1.1: rVP2 protein production 112 
The nucleotide sequences of Seg-2 from different BTV strains (Table 1) downloaded from 113 
the Genbank database (https://www.ncbi.nlm.nih.gov/genbank/), were codon op- 114 
timised for plant expression, then synthesised by GeneArt (ThermoFisher Scientific), 115 
with a sequence encoding a 6xHis-tag inserted at the C-terminus (to enable purification 116 
by immobilised metal affinity chromatography (IMAC)), and flanking AgeI and XhoI re- 117 
striction sites [40]. These DNA constructs were individually cloned into pEAQ-HT ex- 118 
pression vectors to generate pEAQ-HT-BTV-VP2 plasmids for each BTV strain [43, 44]. 119 
Plant expression and purification of VP2 proteins has previously been described [23].   120 
 121 
2.1.2: Phylogenetic comparisons of VP2 proteins and subdomains 122 
Full-length aa sequences for VP2, or VP2 sub-domains were aligned using Clustal X 123 
programme (http://www.clustal.org/clustal2/). Alignment files were converted into the 124 
MEGA format using MEGA X software (https://www.megasoftware.net/). Neighbour- 125 
joining phylogenetic trees were constructed in MEGA X, using the p-distance algorithm 126 
(pairwise deletion). Bootstrap (500 replications) analysis was used to test the robustness 127 
of phylogenetic groupings. 128 
 129 
2.2: Virus culture and titration 130 
Isolates of field and ‘reference’ strains of different BTV serotypes (Table 1) obtained from 131 
the Orbivirus Reference Collection (ORC) at the Pirbright Institute (TPI), 132 
(https://www.reoviridae.org/dsRNA_virus_proteins/ReoID/BTV-Nos.htm) were used to 133 
infect 80–90% confluent monolayers of baby hamster kidney (BHK) cells, in T75 cm2 tis- 134 
sue culture flasks. The inoculum was prepared using 4.5 ml of Eagles medium supple- 135 
mented with 100 IU/ml penicillin, 100µg/ml streptomycin, containing 500 μl of the virus 136 
isolate, mixed and added to the cell layer, then incubated at room temperature for 30 137 
minutes. Cell media (22 ml) was added and flasks were incubated at 37°C in 5% CO2 then 138 
monitored daily for cytopathic effect (CPE). From day 5 onwards, cells showing 90% CPE 139 
were harvested, centrifuged to pellet cell debris for 5 minutes at 800 x g.   140 
141 
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Table 1: BTV strains and VP2 sequences used for VP2 expression, SNT and phylogenetic comparisons 142 
BTV serotype and 
country / region, 
or reference-strain serotype* 
 [ORC collection No**] 
Serotype, 
topotype 








Virus used in 








BTV-1w Gibraltar [GIB2007/06] 1w  (H) Yes Yes - KP821004 [46] 
BTV-1*  [RSArrrr/01] 1w  (H) - - Yes AJ585122 [27] 
BTV-1e Greece [GRE2001/09] 1e  (H) - - Yes - - 
BTV-1e Greece [GRE2001/06] 1e  (H) Yes Yes - KP821006 [46] 
BTV-2 Tunisia [TUN2000/01] 2w  (I) Yes No - KP821037 [45] 
BTV-2 * [RSArrrr/02] 2w  (I) - - Yes AJ585123 [27] 
 
BTV-3 * [RSArrrr/03] 3w  (B) - - Yes AJ585124 [27] 
BTV-4e China (1996) YTS-4 4e  (A) Yes No - JX560414 [47] 
BTV-4w Cyprus [RSArrrr/04] 4w  (A) - - Yes AJ585125 [27] 
BTV-4w Morocco [MOR2009/09] 4w  (A) Yes Yes - KP821064 [46] 
BTV-5* [RSArrrr/05] 5w  (E) - - Yes AJ585126 [27] 
BTV-6*  [RSArrrr/06] 6w  (C) - - Yes AJ585127 [27] 
BTV-6w Netherlands [NET2008/05] 6w  (C) Yes Yes - GQ506473 [40] 
BTV-7 * [RSArrrr/07] 7w  (F) - - Yes AJ585128 [27] 
BTV-8 * [RSArrrr/08] 8w  (D) - - Yes AJ585129 [27] 
BTV-8w Netherlands [NET2008/03] 8w  (D) Yes Yes - KP821074 [45] 
BTV-9 * [RSArrrr/09] 9w  (E) - - Yes AJ585130 [27] 
BTV-9e India (2002) MBN 
 
 
9e  (E) Yes No - JF443156 [48] 
BTV-9w Libya [LIB2008/03] 9w  (E) Yes No - KP821087 [46] 
BTV-10 Portugal [RSArrrr/10] 10w  (A) Yes No Yes AJ585131 [27] 
Germany (2010) BTV-11_DE 11w  (A) Yes Yes - JQ972852 [49] 
BTV-11* [RSArrrr/11] 11w  (A) - - Yes AJ585132 [27] 
BTV-12*[RSArrrr/12] 12w  (G) - - Yes AJ585133 [27] 
BTV-13* [RSArrrr/13] 13w  (B) - - Yes AJ585134 [27] 
BTV-14* [RSArrrr/14] 14w  (C) - - Yes AJ585135 [27] 
BTV-14 Russia [RUS2011/01] 14w  (C) Yes Yes - KP821096 [46] 
BTV-15 * [RSArrrr/15] 15w  (J) - - Yes AJ585136 [27] 
BTV-16 * [RSArrrr/16] 16e  (B) - - Yes AJ585137 [27] 
BTV-16w Nigeria [NIG1982/10] 16w  (B) Yes No - AJ585150 [27] 
BTV-16e Greece [GRE2008/10] 16e  (B) Yes No - KP820990 [46] 
BTV-17w*[RSArrrr/17] 17w  (A) - - Yes AJ585138 [27] 
BTV-18w* [RSArrrr/18] 18w  (D) - - Yes AJ585139 [27] 
BTV-19w* [RSArrrr/19] 19w  (F) - - Yes AJ585140 [27] 
BTV-20e * [RSArrrr/20] 20e  (A) - - Yes AJ585141 [27] 
BTV-21e * [RSArrrr/21] 21e  (C) - - Yes AJ585142 [27] 
BTV-22w * [RSArrrr/22] 22w  (G) - - Yes AJ585143 [27] 
BTV-23e *[RSArrrr/23] 23e  (D) - - Yes AJ585144 [27] 
BTV-24 * [RSArrrr/24] 24w  (A) - - Yes AJ585145 [27] 
BTV-25 Switzerland (TOV **) 25   (K) Yes Yes - EU839840 [10] 
BTV-26 Kuwait [KUW2010/02] 26  (K^^) Yes Yes Yes HM59064
2 
[42] 
BTV-27 Corsica (2015) Strain 379 27  (K) Yes Yes - KM200718 [50] 
BTV-27 [COR2014/01] 27  (K) - - Yes KU760988 [51] 
* BTV reference strain. **Data concerning BTV isolates held in the orbivirus reference collection (ORC) can be 143 
obtained at https://www.reoviridae.org/dsRNA_virus_proteins/ReoID/BTV-Nos.htm. ** Toggenberg orbivirus.  144 
^ The nucleotypes of BTV srotypes / isolates are based on phylogenetic analyses of BTV genome segment 2 [24, 145 
42]. ^^ BTV-26 was previously assigned to nucleotype ‘L’ [42]. However, based on data presented here showing 146 
relationships between the novel serotypes, we have amalgamated nucleotypes K and L and included BTV-25, -26 147 
and -27 in nucleotype K.  148 
Viruses 2021, 13, x FOR PEER REVIEW 5 of 34 
 
 
Viruses in tissue culture supernatants were titrated in 96 well tissue culture plates 149 
(NUNC) as 6 well repeats, containing 100 μl of log10 serial dilutions (from 10-1 to 10-7, 150 
including 2 half log10 dilutions at 10-3.5 and 10-4.5) in DMEM, containing penicillin and 151 
streptomycin (100 IU/ml and 100 μg/ml respectively). Culture medium was used in an 152 
uninfected control. Vero cells (50 μl, containing 2 x 105 cells/ml) were added to all wells. 153 
Plates were incubated at 37°C in 5% CO2 and analysed for CPE (which are clearly visible 154 
as rounded up and detached cells) by inverted light microscopy on day 6 and 7.  Read- 155 
ings on day 7 were used for the final calculation of virus titre using the Spearman-Karber 156 
formula [45].  157 
 158 
2.3. Animals  159 
All animal studies (antiserum production) were performed in the animal facilities at TPI, 160 
using ten 14-week-old female New Zealand white rabbits. Throughout the study, daily 161 
health checks were performed, and supplemental environmental enrichment provided 162 
(see also ethical statement). 163 
 164 
Rabbit and sheep polyclonal antisera  165 
Polyclonal rabbit antisera were raised against ten of the plant expressed recombinant 166 
BTV-VP2 (rVP2) proteins (Table 1). Each inoculum consisted of freshly prepared, purified 167 
rVP2 protein, at a concentration of 250 μg/ml, with 500 μl Montanide ISA V50 (Seppic) 168 
adjuvant (v/v), in a total volume of 1 ml PBS. Inocula were vortexed to mix, until a stable 169 
homogenous emulsion was formed, then stored on ice. Each inoculum was administered 170 
to a single rabbit. Each animal received subcutaneous vaccinations on days 0, 15 and 32, 171 
a total of 1ml on each occasion, which was split across four different injection sites (250 172 
μl each site), giving a cumulative final total by day 32, of 3ml per animal. At day 46, 173 
animals were humanely culled by an overdose of anaesthesia and blood was collected 174 
via a cardiac bleed directly into red-top serum blood vacutainers (from BD), without anti- 175 
coagulant. The blood was allowed to clot for 1 hour at room temp, then at 4C overnight. 176 
Serum was collected and stored at -20C. 177 
A panel of BTV reference sheep-antisera, raised against the reference field-strains of BTV 178 
serotypes -1 to -24, and -26, was provided by the Non-vesicular Reference Laboratory 179 
(NVRL) at TPI. These antisera were derived from sheep previously infected with the 180 
reference bluetongue viruses identified in Table 1. 181 
 182 
2.4 Serological assays 183 
2.4.1.Antibodies 184 
Polyclonal rabbit antisera, raised against individual BTV-rVP2 proteins, were purified 185 
using the NAb Protein A Plus Spin Kit (ThermoFisher Scientific) as per manufacturer’s 186 
instructions. Antibody concentration (mg/ml) was determined by spectrophotometer at 187 
an absorbance of 280nm. Secondary antibodies were obtained from commercial suppli- 188 
ers, diluted and used as follows: goat anti-rabbit IgG H&L (HRP; Abcam), 1:2000; donkey 189 
anti sheep IgG (HRP; Sigma Aldrich), 1:5000.  190 
 191 
 192 
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2.4.2. Indirect-ELISA:  193 
An indirect ELISA (I-ELISA) was developed using purified BTV-rVP2 proteins as target 194 
antigens, as previously described [23]. Reagents/buffers were used in 100 μl volumes 195 
unless specified otherwise. Briefly, 96 well maxisorb or nickel coated ELISA plates 196 
(ThermoFisher) were coated with 2 µg/ml of recombinant protein (VP2) in 0.05M 197 
carbonate-bicarbonate buffer (pH9.6) (supplied as capsules by Sigma Aldrich, dissolved 198 
in PBS) sealed and incubated overnight at 4C. Control wells were coated with coating- 199 
buffer only, or with 2 µg/ml of purified pEAQ-HT (EV) only. Plates were washed three 200 
times with PBS, 0.05% Tween 20, blocked using PBS, 5% BSA for 1 hour at 37C, then 201 
washed again. Test sera were titrated in duplicate, at dilutions of 1:40 to 1:40,960 (rabbit 202 
antisera) and 1:10 to 1:10,240 (sheep antisera), in PBS with 5% skimmed milk powder, 203 
with species-specific ‘negative’ serum used as controls. Plates were incubated at room 204 
temperature on an orbital shaker for 1 hour, washed again and the species-specific HRP 205 
labelled secondary antibody was added. Plates were covered and incubated for 1 hour at 206 
room temperature then washed as previously described. OPD substrate (SIGMAFAST) 207 
was added to each test well and incubated in the dark for 15 to 30 minutes then read 208 
immediately at 450 nm using a Multiskan FC microplate photometer. The OD value of 209 
the negative control at each dilution was deducted from the corresponding OD value of 210 
the test serum at the same dilution to eliminate background detection. A cut-off value for 211 
positive titres was determined as the mean of the negative control plus one standard 212 
deviation. The final antibody titre for the test serum was defined as the inverse of the 213 
highest dilution, where the mean value for duplicates was equal to or above the cut-off 214 
value. 215 
  216 
2.4.3 Serum Neutralisation Test (SNT) 217 
SNTs were performed as previously described [23] using Vero cells. Plates were scored 218 
on days 5–7 for the obvious CPE caused by BTV infection (rounding up and detachment 219 
of cells), by visual observation using an inverted light microscope. The final reads (day 220 
7) were used to determine antiserum neutralisation titres, as the inverse of the dilution 221 
of serum giving a 50% end-point, as calculated using the Spearman Karber method [45]. 222 
 223 
2.5. Antigenic cartography  224 
Multi-dimensional antigenic maps were made using antibody titres generated by I- 225 
ELISA to quantify and visualise cross-reactivity between rVP2 proteins from different 226 
BTV-strains, using the ACMACS website https://acmacs-web.antigenic-cartography.org/ 227 
as described previously [52]. Briefly, a target distance between each serum and virus was 228 
calculated by subtracting the Log2 of the titre for that virus, from the Log2 of the 229 
maximum titre for that serum against any of the other rVP2 proteins. An rVP2 protein 230 
that reacts at a high titre with an individual serum, therefore has a smaller target distance 231 
to that serum and they are placed closer together on a visual map. Conversely, a low 232 
antibody titre detected in a reaction with a given rVP2 protein will give a larger target 233 
distance. The target distances, which quantify the antigenic relationships between BTV 234 
serotypes / topotypes, are denoted as ‘Antigenic Units’ (AU). One AU is equal to a two- 235 
fold change in titre of antiserum regardless of the magnitude of the titre. 236 
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Multidimensional scaling was used to minimise the differences (sum-squared error) 237 
between the ‘target distance’ and ‘map distance’ (how well the map represents the target 238 
distances generated). The position of each virus and antiserum is therefore determined 239 
by the relationships and position of each antiserum relative to all other viruses. To 240 
minimise the sum-squared error, and obtain a map of best fit, multiple random restart 241 
optimisations (500 times) were carried out, generating maps in two to five dimensions. 242 
Correlation between target distance and map distance was used to assess fit of the maps 243 
to the data. There was minimal improvement in overall error and fit by increasing 244 
dimensions above 3-D, (Table 1S [supplementary]) and maps are therefore presented in 245 
3D only.  246 
Antigenic distances (units) were calculated for the expressed BTV-rVP2 proteins, using 247 
(bAb) data from I-ELISA, with either rabbit anti-rVP2 sera, or sheep anti-BTV reference 248 
antisera. (Tables S2 and S3 [supplementary]). However, due to their higher serotype- 249 
specificity in SNT, an insufficient number of cross-serotype nAb reactions were detected 250 
using either the rabbit or sheep antiserum panels, to support reliable antigenic 251 
cartography. 252 
 253 
3. Results 254 
3.1: Antigenic cross-reactivity of rabbit antisera against rVP2 proteins by I-ELISA 255 
Rabbit antisera, raised against the plant expressed rVP2 proteins from ten BTV strains 256 
(Table 1), were tested by I-ELISA using rVP2 proteins from seventeen BTV strains as 257 
target antigens. Widespread and often high titre cross-reactions were observed (Table 258 
2), to the extent that the anti-rVP2 sera for BTV-6w, BTV-8w, BTV-11w and BTV-27, 259 
reacted at different titres with all of the BTV rVP2 proteins tested. The remaining rabbit 260 
antisera also recognised most of the rVP2 proteins, apart from anti-BTV1e-rVP2, which 261 
only reacted with rVP2 of BTV-1e and -1w and -26.  262 
Seven of the rabbit antisera (against rVP2 of BTV-1w, -1e, -4w, -8w, -11w, -14w and -27) 263 
showed highest antibody titres in I-ELISA with their homologous rVP2 proteins (titres of 264 
640 to 40,960). High titre cross-reactions were also observed between the rabbit anti-rVP2 265 
sera and rVP2 proteins, derived from eastern and western topotypes of the same 266 
serotypes, BTV-1e and BTV-1w (titres ≥ 20,480), and to a lesser extent between BTV-4w 267 
and BTV-4e (titre ≥5120) (Table 2). The remaining three rabbit antisera (against rVP2 of 268 
BTV-6w, -25 and -26: highlighted in blue in Table 2) showed highest titres in one or more 269 
of the heterologous reactions. The lowest homologous reaction was between rVP2 and 270 
anti-rVP2 of BTV-25, at a titre of 640. 271 
In some but not all cases, high titre cross-reactions were also observed in I-ELISA, 272 
between rabbit anti-rVP2 sera and rVP2 proteins derived from heterologous serotypes 273 
but from within the same nucleotype (Table 1, Figure 1). For example, the anti-BTV11w- 274 
rVP2 serum reacted at the same high titre (40,960) with the rVP2 proteins of BTV-11w 275 
and BTV-4w, both belonging to nucleotype A (Table 2). In the reverse reactions, the anti- 276 
BTV4w-rVP2 serum also cross-reacted at a high titre (20,480) with BTV11w-rVP2, 277 
although this was at a lower titre than in the homologous reaction (40,960). The rabbit 278 
anti-rVP2 sera and rVP2 proteins derived from BTV-4w and BTV-11w sera also cross- 279 
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reacted but at lower titres, with most of the other rVP2 proteins or anti-rVP2 sera from 280 
heterologous BTV serotypes and topotypes.  281 
However, some high-titre cross-reactions were also observed between serotypes 282 
belonging to different nucleotypes. For example, the anti-BTV4w-rVP2 serum 283 
(nucleotype A) reacted at a high titre (40,960) with rVP2 of BTV-1w (nucleotype H). In 284 
the reverse reaction the anti-BTV1w-rVP2 serum, which had an homologous titre of 285 
40,960, showed a much lower titre (1280) with rVP2 of VTV4w.   286 
 287 
Table 2: I-ELISA titres for rabbit anti-BTV-rVP2 sera tested against BTV rVP2 proteins 288 
BTV strain providing sequence 
data for rVP2 expression  
Rabbit anti-BTV-rVP2 sera 
1w 1e 4w 6w 8w 11w 14w 25 26 27 
BTV-1w [GIB2007/06] 40960 20480 40960 2560 640 10240 1280 1280 1280 2560 
BTV-1e [GRE2001/06 ] 40960 40960 320 5120 1280 1280 - 640 640 2560 
BTV-2w [TUN2000/01] 10240 - 80 160 40 1280 40 40 40 640 
BTV-4w [MOR2009/09] 1280 - 40960 2560 1280 40960 2560 1280 2560 5120 
BTV-4e China YTS-4 1280 - 5120 2560 320 10240 320 5120 5120 10240 
BTV-6w [NET2008/05 ] 640 - 640 2560 160 1280 160 320 320 2560 
BTV-8w [NET2008/03] - - - 640 40960 160 - - - 160 
BTV-9w [ LIB2008/03] 1280 - 1280 2560 320 2560 320 2560 2560 10240 
BTV-9e India MBN 2560 - 5120 5120 2560 5120 640 2560 5120 5120 
BTV-10w [RSArrrr/10] 1280 - 2560 2560 1280 2560 320 2560 2560 10240 
BTV-11w Germany (BTV-11_DE) 1280 - 20480 1280 160 40960 640 1280 2560 10240 
BTV-14w [RUS2011/01] 10240 - - 5120 1280 2560 40960 2560 2560 10240 
BTV-16w [NIG1982/10] 1280 - 1280 5120 640 2560 320 2560 5120 5120 
BTV-16e [GRE2008/10] 1280 - 320 5120 640 5120 1280 1280 2560 2560 
BTV-25 Switzerland (TOV) 80 - 640 2560 40 1280 - 640 640 5120 
BTV-26 [KUW2010/02] 2560 40 5120 5120 2560 10240 1280 2560 5120 10240 
BTV-27 Corsica (379) 2560 - 2560 5120 1280 5120 1280 2560 10240 10240 
Table 2: Antibody titres in reactions with the homologous rVP2 protein are shown in red, bold and underlined. 289 
Titres for homologous reactions that were lower than one or more heterologous reaction are shown highlighted in 290 
blue. Boxes indicate the reactions of different virus topotypes, with sera from the homologous serotype.. The final 291 
antibody titre for the test serum was defined as the inverse of the highest dilution, where the mean value for 292 
duplicates was equal to or above the cut-off value. 293 
 294 
Although the rabbit anti-BTV1e-rVP2 serum was the least cross-reactive by ELISA, it did 295 
react with rVP2 of BTV-1w (titre of 40,960), and at a low titre with rVP2 of BTV-26 (titre 296 
of 40). In contrast, the rVP2 protein of BTV-1e was recognised by all of the heterologous 297 
rVP2 antisera, therefore showing multiple one way cross-reactions.   298 
The serum against VP2 of the ‘novel’ serotype BTV-27, appeared to be highly cross- 299 
reactive (showing the same titre of 10,240) with the rVP2 proteins of BTV-27, -4e, -9w,   300 
-10w, -11w, -14w, and -26 (representing four different nucleotypes; Figure 1).  Although 301 
the anti-BTV8w-rVP2 serum (homologous titre of 40,960) recognised all seventeen 302 
expressed rVP2 proteins, the BTV8w-rVP2 protein itself (homologous reaction titre of 303 
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40,960) only cross-reacted with the anti-rVP2 sera of BTV-6w (at a titre of 640), BTV-11w 304 
and BTV-27 (each at a titre of 160), none of which belong to the same nucleotype, D. 305 
 306 





























Figure 1: A neighbour-joining phylogenetic tree constructed with aa sequences of VP2(OC1) of BTV-1 to 336 
BTV-27 depicting phylogenetic groupings. The tree was generated using the p-distance algorithm (pairwise 337 
deletion) implemented in the MEGA X software program. VP2/Seg-2 nucleotypes are indicated as previously 338 
reported [41] although with novel serotypes BTV-25, -26 and -27 are included in nucleotype (K). 339 
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3.2 : Cross-reactivity of rabbit anti-rVP2 in serum neutralisation tests (SNT)  340 
SNTs were performed using reference strains (n=26) of BTV-1 to -24, -26 and -27, to assess 341 
the titres and serotype-specificity of neutralising antibodies (nAbs) present in the ten 342 
anti-rVP2 rabbit antisera (Table 3). In each case, apart from BTV-27, highest titre nAbs 343 
were detected against the homologous BTV serotype, although titres were generally 344 
much lower than by I-ELISA (ranging from 1:15 to 1:690).   345 
 346 































Table 3: Antiserum neutralisation titre is defined as the inverse of the dilution of serum giving a 50% 378 
end-point, using the Spearman Karber method [45]. Titres of nAbs against a strain of the homologous 379 
serotype and topotype are shown in red, bold and underlined. The box indicates cross-reactions 380 
between different topotypes of BTV-1. The absence of detectable neutralising antibody titres (<1:10) 381 
is shown by a ‘dash’. Titres that were lower in the homologous reaction than in one or more 382 
heterologous reactions are shaded in blue (BTV-27).  383 
BTV reference strain 
[ORC number*]  
Rabbit anti-BTV-rVP2 sera 
1w 1e 4w 6w 8w 11w 14w 25w 26e 27w 
BTV-1w [RSArrrr/01] 140 60 - - - - - - - - 
BTV-1e [GRE2001/09] 120 60 - - - - - - - - 
BTV-2w [RSArrrr/02] - - - - - - - - - - 
BTV-3w [RSArrrr/03 ] - - - - - - - - - - 
BTV-4w [RSArrrr/04 ] - - 240 - - 15 10 - - - 
BTV-5w [RSArrrr/05] - - - - - - - - - - 
BTV-6w [RSArrrr/06] - - - 690 - - - - - - 
BTV-7w [RSArrrr/07] - - - - - - - - - - 
BTV-8w [RSArrrr/08 ] - - - - 90 - - - - - 
BTV-9w [RSArrrr/09  ] - - - - - - - - - - 
BTV-10w [RSArrrr/10] - - - - - - - - - - 
BTV-11w [RSArrrr/11] - - 20 - - 120 - - - - 
BTV-12w [RSArrrr/12] - - - - - - - - - - 
BTV-13w [RSArrrr/13] - - - - - - - - - - 
BTV-14w [RSArrrr/14] 40 - - - - - 600 - - - 
BTV-15w [RSArrrr/15] - - - - - - - - - - 
BTV-16e [RSArrrr/16 ] - - - - - - - - - - 
BTV-17w [RSArrrr/17] - - 70 - - 30 - - - 20 
BTV-18w [RSArrrr/18] - - - - - - - - - - 
BTV-19w [RSArrrr/19] - - - - - - - - - - 
BTV-20e [RSArrrr/20] - - 160 - - 80 10 - - - 
BTV-21e [RSArrrr/21] - - - - - - 10 - - - 
BTV-22w [RSArrrr/22] - - - - - - - - - - 
BTV-23e [RSArrrr/23] - - - - 30 - 10 - - - 
BTV-24w [RSArrrr/24] - - 15 - - 10 - - - - 
BTV-26e [KUW2010/01] - 30 - 20 10 20 - 30 40 40 
BTV-27w [COR2014/01] - - - - - - - 10 15 15 
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Fewer cross-serotype nAb reactions were observed than in the I-ELISA, and most were 384 
between viruses belonging to the same nucleotype. For example the anti-BTV4-rVP2 sera 385 
showed low levels of cross neutralisation with BTV-11w, -17w, -20e and -24w (Table 3), 386 
while the anti-BTV11-rVP2 sera contained nAbs that also reacted with BTV-4w, -11w - 387 
17w, -20e, and -24w, all of which belong to nucleotype A. 388 
Evidence of intra-nucleotype cross-serotype neutralisation was also seen between BTV- 389 
14w and BTV-21e, and between BTV-8w and BTV-23e, in nucleotypes C and D, 390 
(respectively). Although a strain of BTV-25 that would replicate in cell culture was not 391 
available for these studies, the antisera raised against rVP2 of BTV-25, -26 and -27, all 392 
cross-neutralised BTV-26 and -27 (Table 3). Based on these results and the similarities 393 
detected by phylogenetic analyses of VP2 (Figure 1), we have re-grouped these three 394 
‘novel’ strains / serotypes within nucleotype K (previously grouped in nucleotypes K and 395 
L) [28, 53].    396 
A few inter-nucleotype nAb reactions were also detected, using the rabbit anti-rVP2 sera: 397 
with evidence of anti-BTV14w-rVP2 s (nucleotype C) neutralising BTV-4w, -20e and -23e 398 
(nucleotypes A and D); anti-BTV1w-rVP2 neutralising BTV-14w (nucleotypes H and C, 399 
respectively); and anti-BTV27-rVP2 neutralising BTV-17w (nucleotypes K and A, 400 
respectively). BTV-26 was the most cross-reactive virus used in SNT, being neutralised 401 
to some extent by seven of the ten rabbit antisera, across five nucleotypes (A, C, D, H, K ), 402 
although anti-BTV26-rVP2 only neutralised BTV-26 and BTV-17w (Table 3).  403 
Further evidence for the serotype specificity of the anti-BTV-rVP2 sera in SNT, was 404 
provided by the neutralisation of reference strains of BTV-1e -1w, -6w and -8w, only by 405 
sera against their homologous strain/serotypes, and by the cross-reaction of eastern and 406 
western topotypes of the BTV-1 (Table 3). Rabbit antisera were not generated against 407 
rVP2 proteins of BTV-2w, -3w, -5w, -7w, -9w, -12w, -13w, -15w, -16e, -18w, -19w and - 408 
22w, however no cross-reactive nAbs were detected against these serotypes in any of the 409 
rabbit sera that were generated against other serotypes, again suggesting serrotype 410 
specificity (Table 3).    411 
 412 
3.3: Cross-reactivity of BTV-rVP2 proteins with sheep anti-BTV reference antisera in 413 
I-ELISA  414 
Sheep reference-antisera against BTV serotypes -1 to -24 (excluding BTV-7) and BTV-26 415 
(n=24), were tested in I-ELISA using rVP2 proteins as target antigens (Table 4). Overall, 416 
these sheep antisera showed fewer cross-reactions, and generally at lower titres 417 
(maximum titre of 10,240) than the rabbit anti-rVP2 sera (maximum titres 1:40,960). 418 
However, nine of the sheep antisera (anti-BTV-2w, -5w, -8w, -10w, -11w, -16e, -17w, -19w 419 
and -20e) still recognised all or most of the seventeen rVP2 proteins from different 420 
serotypes (Table 4).  421 
The most cross-reactive protein was rVP2-BTV-1e, which was recognised in I-ELISA by 422 
17 of the 24 sheep antisera; unlike rVP2 of BTV-1w, which was recognised by only eight 423 
sheep antisera (against BTV-1w, -2w, -5w, -6w, -10w, -16e, -17w and -20e).   424 
  425 
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BTV rVP2 antigens 
1w 1e 2w 4w 4e 6w 8w 9w 9e 10w 11w 14w 16w 16e 25 26 27 
BTV-1w 5120 1280 - - -  40 - - - - - - - - - - - 
BTV-2w 10 160 10240 80 40  10240 80 20 40 160 20 160 80 40 160 160 20 
BTV-3w - 20 - 10 -  80 - - - - - - - - 20 - - 
BTV-4w - - - 10240 -  - - - - - - - - - - - -  
BTV-5w 10 60 20 80 40  320 80 40 80 160 20 80 20 160 320 80 20 
BTV-6w 5120 10 - - - 20 - - - - - - - - - - - 
BTV-8w - 40 - 80 20  640 2560 20 40 80 - - 160 320 640 80 - 
BTV-9w - - - 640 -  - - 5120 10240 - - - - - - - - 
BTV-10w 320 1280 1280 5120 320  2560 1280 640 1280 1280 320 160 320 5120 640 1280 320 
BTV-11w - 40 - 80 20 320 40 10 20 160 40 10 - - 80 10 20 
BTV-12w - 20 - - - 40 - 40 80 - - - - - 80 - - 
BTV-13w - 10 - - 10 - - - 10 - - - - - - - - 
BTV-14w - - - - - - - - - - - 1280 - - - - - 
BTV-15w - - - - - - - - - - - 160 - - - - - 
BTV-16e 40 80 40 320 40 320 160 40 40 320 40 - 160 2560 80 40 40 
BTV-17w 20 40 160 320 80 80 20 40 40 320 40 80 160 320 80 20 80 
BTV-18w - - - 10 - - - 80 - - - - - - - - 10 
BTV-19w - 20 10 10 10 40 20 320 - 80 20 - - - 20 10 20 
BTV-20e 10 40 40 1280 20 80 40 20 20 80 - - 20 40 20 20 40 
BTV-21e - 10 - 10 - - - 40 10 - - 40 - - - - 20 
BTV-22w - - - 20  - - - - - - - - - - - - 
BTV-23e - - - - - - - 160 - - - - - - - - 10 
BTV-24w - 10 - 80 - - - 160 - - - - - - - - 10 
BTV-26 - 10 - - - - - 1280 - 40 - - - - - 10 - 
Table 4: Titres for BTV reference antisera, detected in I-ELISA using expressed rVP2 proteins as target antigens. 427 
The titres detected against rVP2 proteins from strains of the homologous serotype and topotype, are shown in red, 428 
bold and underlined. The boxes indicate homologous serotype reactions for different topotypes within the same 429 
serotype. Titres for homologous reactions that are lower than one or more heterologous reaction are shaded in blue. 430 
The final antibody titre for an individual test serum in reaction with a specfic rVP2 antigen, is defined as the inverse 431 
of the highest dilution, where the mean value for duplicates was equal to or above the cut-off value.  *The 432 
reference sheep antisera for BTV-7 failed to recognise the homologous reference virus strain, or any other BTV 433 
strain tested and it has therefore been excluded from this study.  434 
All of the sheep reference-antisera recognised the rVP2 protein from their homologous 435 
BTV serotype and topotype (where available), showing highest titres in six out of eleven 436 
of these reactions. However, four of the reference antisera (anti-BTV-6w, -10w -11w and 437 
-27) showed higher titres in reactions with rVP2 of heterologous serotypes. This includes 438 
the BTV-6 and BTV-26 reference sera, which showed only very low positive titres (1:20 439 
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and 1:10 respectively) with of rVP2 proteins from strains of their homologous serotype / 440 
topotype.  441 
The ovine anti-BTV-1w serum recognised rVP2 proteins of both BTV-1w and (at a lower 442 
titre) BTV-1e, and the sheep antisera against BTV-16e reacted with rVP2 of both eastern 443 
and western topotypes of BTV-16, although again the titre was higher with the 444 
homologous protein of the eastern strain. However, anti-BTV-9w showed a higher titre 445 
with VP2 of BTV-9e than with rVP2 of BTV-9w, and rVP2 of BTV-4e was not recognised 446 
by the anti-BTV-4w serum.   447 
The least cross-reactive sheep sera were against BTV-4w, -14w -15w, which only 448 
recognised homologous-serotype rVP2 proteins and consequently showed one-way 449 
reactions with the more cross-reactive rVP2 proteins (mentioned above). The rVP2 450 
protein of BTV-2w showed an intermediate level of cross-reactivity by ELISA, being 451 
recognised by 7 of the 24 sheep reference-antisera (against BTV-2w, BTV-5w, BTV-10w, 452 
BTV-16e, BTV-17w, BTV-19w and BTV-20e). However, the anti-BTV-2w sheep serum 453 
reacted with all 17 of the available rVP2 BTV proteins (Table 5), providing additional 454 
evidence for one-way cross-reactions in ELISA with rVP2 of ten BTV strains. 455 
 456 
3.4: Cross-reaction of sheep BTV reference-antisera in SNT with BTV reference strains 457 
In contrast to the results from I-ELISA, most reactions detected in SNT with the sheep 458 
reference-antisera, were serotype-specific and consistently at higher titres (60 up to 459 
10,000) than observed in SNT with the rabbit anti-rVP2 sera (titres of 15 up to 600: Table 460 
3).  This reversed the trend seen in the I-ELISA, which showed generally lower bAb ti- 461 
tres in the sheep reference-antisera, as compared to the rabbit anti-rVP2 sera (Tables 2 462 
and 3).  463 
Only the sheep anti-BTV-14 serum showed a slightly lower SNT titre with its 464 
homologous virus (1:560) than the rabbit anti-rVP2 sera against the same serotype (1:600). 465 
Unsurprisingly (since the ‘gold-standard’ for BTV-serotype determination is cross- 466 
neutralisation by antisera against reference isolates of the same serotype [35, 24, 27]) the 467 
sheep anti-BTV-1w reference-serum cross-neutralised both topotypes of BTV-1 (east and 468 
west), although the heterologous reaction to BTV-1e was at a lower titre (1:40) than with 469 
the homologous topotype (1:240).  470 
Although some cross-reactions were observed in SNT with the sheep sera, all of them 471 
were at lower-titres than those recorded in reactions with the homologous strain of the 472 
same serotype, unlike those with the rabbit anti-rVP2 sera (compare Tables 3 and 5). The 473 
most cross-reactive BTV strain was BTV-26, assigned to nucleotype K, although the nAb 474 
titres detected were low (against 7 other serotypes), even with its homologous antiserum 475 
(titre of 60). The most cross-reactive sheep reference-serum was against BTV-3w 476 
(homologous titre 560), which neutralised four heterologous serotypes in SNT, although 477 
at lower titres ≤ 100. The BTV-4w antiserum, which neutralised its homologous strain (at 478 
a titre of 320) and BTV-26 (titre of 1:10), also showed low level nAbs against BTV-17w 479 
(titre of 32) and BTV-20e (titre of 32), both of which belong to the same nucleotype as 480 
BTV-4w (nucleotype A). However, the BTV-5 antiserum, which neutralised its 481 
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homologous virus strain and BTV-9w (at titres of 3160 and 10) respectively, both of which 482 
belong to nucleotype E, also neutralised BTV-10w (titre of 320) and BTV-26e (titre of 10), 483 
which belong to nucleotypes A and K, respectively.  484 
The least cross-reactive sheep reference-antisera against BTV-10w, BTV-11w, BTV-14w 485 
and BTV-16e, only neutralised the homologous virus strains.   486 
 487 
Table 5: nAb titres of sheep BTV reference-antisera in SNT using reference strains of BTV-1 to -24, -26 and -27 488 
Table 5: Antiserum neutralisation titre was defined as the inverse of the serum dilution giving a 50% end-point, using 489 
the Spearman Karber method [45].  * BTV reference virus strains (Table 1) were used in SNT, as well as the isolates: 490 
Greece BTV-1e [GRE2001/09]; BTV-26 [KUW2010/02] and BTV-27 [COR2014/01]. **The post-infection anti-BTV-7w 491 
reference serum failed to react with any of the viruses in these assays (including the homologous strain). It has 492 
therefore been ommitted from these assays. Titres for homologous reactions are shown in red, bold and underlined. 493 
The box shows reactions of the ovine anti-BTV-1w serum with eastern and western topotypes of BTV-1. 494 
BTV 
Strain* 
Sheep anti-BTV reference sera** 
1w 2w    3w 4w 5w 6w 8w 9w 10w 11w 12w 13w 14w 15w 16e 17w 18w 19w 20e 21e 22w 23e 24w 26 
BTV-1w 10240 - - - - - - - - - - - - - - - - - - - - - - - 
BTV-1e 40 - - - - - - - - - - - - - - - - - - - - - - - 
BTV-2w - 160 - - - - - - - - - - - - - - - - - - - 10 - - 
BTV-3w - - 560 - - - - - - - - - - - - - - - - - - - - - 
BTV-4w  - - - 320 - - - - - - - - - - - 5 - - 32 - - - - - 
BTV-5w - - - -  3160  - - 10 - - - - - - - - - - - - - - - - 
BTV-6w 3.2 - 10 - - 1780 - - - - - 32 - - - - - - - 32 - - - - 
BTV-7w - - - - - - - - - - - - - - - - - - - - - - - - 
BTV-8w - - - - - - 1000 - - - - - - - - - - - - - - 10 - - 
BTV-9w - - - - 10 - - 1780 - - - - - - - - - - - - - - - - 
BTV-10w - - - - 320 - - - 10k - - - - - - - - - - - - - - - 
BTV-11w - - - - - - - - - 10k - - - - - - - - - - - - - - 
BTV-12w - - 10 - - - - - - - 1000 - - - - - - - - - - - - - 
BTV-13w - - - - - - - - - - - 1780 - - - - - - - - - - - - 
BTV-14w - - - - - 60 - - - - - - 560 - - - - - - - - - - - 
BTV-15w - - - - - - 20 - - - - - - 560 - - - - - - - - - - 
BTV-16e - - 100 - - - - - - - - - - - 320 - - - - 32 - - - - 
BTV-17w - - - 32 - - - - - - - - - - - 100 - - 5 - - - - - 
BTV-18w - - - - - - - - - - - - - - - - 1000 - - - - - - - 
BTV-19w - - - - - - - - - - - - - - - - - 10k - - - - - - 
BTV-20e - - - 3.1 - - - - - - - - - - - 32 - - 100 - - - - - 
BTV-21e - - - - - 32 - - - - - - - - - - - - - 180 - - - - 
BTV-22w - - - - - - - - - - - - - - - - - - - - 1780 - - - 
BTV-23e - - - - - - 32 - - - - - - - - - - - - - - 1000 - - 
BTV-24w - - - - - - - - - - - - - - - - - - - - - - 1000 - 
BTV-26* - 15 10 10 10 - - - - - 10 10 - 10 - - - - - - - - - 60 
BTV-27*  - - - - - - - - - - - - - - - - - - - - - - - - 
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3.5: Mapping antigenic relationships using antigenic cartography 495 
Antigenic cartography was used to compare and visualise the serological relationships 496 
between different BTV strains / serotypes, that were detected in I-ELISA, as multiple 497 
cross-reactions by VP2 specific bAbs present in either rabbit anti-rVP2 sera or sheep anti- 498 
BTV reference sera, reacting with the expressed rVP2 proteins. The titres of individual 499 
antisera (tables 2 and 4) were converted into antigenic units (AUs) (shown as 500 
supplementary data in Table S2 and S3) and used to position the rVP2 proteins from 501 
different virus strains relative to each other in 3D maps (Figures 2). The much higher 502 
serotype-specificity of nAbs in SNT with either the rabbit or sheep antiserum panels 503 
(Tables 3 and 5) resulted in an insufficient number of cross-serotype reactions to support 504 
reliable antigenic cartography of the different BTV reference strains.  505 
Overall, both sets of bAb results (for rabbit or sheep antisera) mapped the rVP2 proteins 506 
of different BTV strains / serotypes as a single large cluster (Figure 2), reflecting multiple 507 
cross-reactions and antigenic relationships between them. Both maps showed 508 
considerable antigenic distances between different topotypes of the same serotype: BTV- 509 
1e and -1w (shown in green in Figure 2), or BTV-4e and -4w (shown in purple), although 510 
somewhat closer relationships were detected between BTV-9e and 9w (shown in red), or 511 
BTV-16e and -16w (shown in orange).  512 
Cross-reactive nAbs were also detected between BTV-1e and -1w, using both sheep and 513 
rabbit antisera in SNT (Tables 3 and 5), reflecting a relatively close phylogenetic 514 
relationship between their VP2 aa sequences (Figure 1). The cross-topotype intra- 515 
serotype reactions of nAbs were not tested for BTV-4, -9 or -16. 516 
The rVP2 proteins derived from BTV strains / serotypes belonging to nucleotype A (BTV- 517 
4e and BTV-4w, BTV-10w, BTV-11w) were grouped in both of the I-ELISA maps (shown 518 
in purple in figure 2) reflecting serological (bAb) relationships between them. The nAb  519 
results (Tables 3 and 5) also showed multiple nAb cross-reactions between viruses 520 
belonging to nucleotype A (BTV-4w, BTV-11w, BTV-17w, BTV-20e, BTV-24w), again 521 
reflecting relatively close phylogenetic relationships detected between their VP2 aa 522 
sequences (Figure 1).  523 
The rVP2 proteins from BTV-26 and BTV-27 (nucleotype K) were positioned relatively 524 
closely to those of BTV-4e and -10w (nucleotype A) in Figure 2A (in reactions with rabbit 525 
anti-rVP2 sera) and rVP2 of BTV-11w (nucleotype A) was positioned very closely to that 526 
of BTV-27 in figure 2B, possibly suggesting an antigenic (bAb) relationships between 527 
these two nucleotypes, which is also indicated by phylogenetic comparisons of VP2 aa 528 
sequences (Figure 1).  529 
The rVP2 proteins of BTV-2w and -8w (nucleotypes D and I, respectively) were placed at 530 
the greatest antigenic distances from each other (AU=10) in the ELISA map based on 531 
reactions with the rabbit anti-rVP2 sera (Figure 2A), but were more closely positioned 532 
based on reactions with the sheep reference sera (Figure 2B), while the rVP2 proteins of 533 
BTV-2w and BTV-1e were placed at greatest distance from each other, suggesting 534 
diversity in the bAb responses of different individual animals, or animal-species.  535 
 536 
  537 
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Figure 2: Three-dimensional antigenic maps illustrating cross-relationships between BTV VP2 proteins.  538 
                      539 
A  (rabbit anti-rVP2 sera)         Front                                          Back 540 
                               541 
B (sheep anti-BTV reference sera)    Front                                       Back 542 
Figure 2: Computational multidimensional scaling, with multiple repeat simulations, were used to position the seventeen rVP2 543 
protein antigens derived from different BTV strains and topotypes, in 3-dimensional maps, based on their antigenic relationships 544 
as determined by I-ELISA, using either A: the ten rabbit anti-BTV-rVP2 sera (Table 2) or B: the 24 sheep anti-BTV reference sera. 545 
The coloured spheres representing rVP2 proteins from different BTV serotypes and topotypes (as indicated) are colour-coded by 546 
nucleotype (see colour key). The grey cubes represent either the ten rabbit sera (panel A) or the 24 sheep sera (panel B). The scale 547 
bar represents one antigenic unit (AU), equivalent to a two-fold change or difference in antibody titre (Table S2 and S4, for the 548 
rabbit and sheep sera respectively). The proteins showing closer antigenic relationships, are therefore positioned closer to each 549 
other in the maps. ‘Front’ and ‘Back’ (rotated 180°) 3D views are shown.  550 
 551 
 552 
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The level of variations observed in the bAb results obtained by I-ELISA with the two 553 
different antisera panels (from sheep and rabbits – tables 2 and 4) was greater than the 554 
differences observed between the two sets of nAB results from SNT (Tables 3 and 5). All 555 
of the virus strains were positioned differently in the 3D cartography maps of bAb 556 
responses (Figures 2A and B) with greater overall antigenic distances calculated for 557 
reactions with the sheep antisera, than the rabbit antisera. However, this was likely 558 
influenced by the availability of sheep reference antisera for a greater number of different 559 
BTV serotypes/strains. The BTV strains that showed the most consistent antigenic 560 
relationships by I-ELISA, using both serum panels were: BTV-1w, -9w, -10w, -11w and - 561 
16e (difference in AU <1, between the rabbit and sheep maps).   562 
  563 
4: Discussion 564 
4.1: Serological reactions between BTV strains 565 
VP2-bAbs (which include both nAbs and non-neutralising antibodies) were detected at 566 
high titres in most of the rabbit and sheep antisera, in I-ELISA with homologous rVP2 567 
proteins (titres of 640 to 40,960 or 10 to 10,240 respectively). These homologous assay 568 
results provide a value for comparison of the cross-reactions detected against rVP2 pro- 569 
teins of the heterologous viruses. The VP2-bAbs, particularly those in the rabbit anti-rVP2 570 
sera, showed multiple high-level cross-reactions with VP2 proteins of the other BTV sero- 571 
types tested, indicating the presence of widely shared epitopes on VP2, many of which 572 
are likely to be non-neutralising. The higher bAb titres detected may also reflect the use 573 
of exactly the same rVP2 proteins as ELISA antigens, that were used to produce the rabbit 574 
antisera, while the sheep sera were raised against ‘reference’ isolates, from different geo- 575 
graphic origins and earlier isolation dates.  576 
 577 
The nAbs detected in the rabbit and sheep antisera (with titres of 10 to 690, or 60 to 10,240, 578 
respectively against the homologous virus serotype and topotype), were more serotype- 579 
specific, particularly in the sheep reference antisera that have been used for many years 580 
(at TPI) to identify the serotype of novel BTV field isolates. The nAb responses detected 581 
in the rabbit sera were generally lower than in the sheep sera, although still primarily 582 
against the homologous serotype. This difference may again reflect the use of more recent 583 
BTV strains from Europe and elsewhere, as a source of the Seg-2 sequences used to gen- 584 
erate the rVP2 proteins, while the sheep reference sera were generated by infections with 585 
the same reference strains used in the SNT. The solubility of the plant-expressed proteins 586 
and their ability to raise nAbs, which are thought to react primarily with conformation 587 
epitopes [22, 54, 55], as well as previous demonstrations that they can assemble as part 588 
of virus like particles [44] collectively indicate that a significant proportion of the BTV- 589 
rVP2 proteins have a native conformation when expressed in plants.  590 
   591 
Earlier studies of neutralising antibodies and clinical observations from vaccination / 592 
challenge studies in sheep or small animals, identified low-level one-way or two-way 593 
cross-reactions between a limited range of BTV serotypes [56-60]. Some of these relation- 594 
ships were unexpected, based on the magnitude of amino acid sequence variations in 595 
VP2 between individual strains [61]. However, the results obtained may have been bi- 596 
ased by use of only a limited range of monoclonal antibodies that recognised conserved 597 
sites shared between the different BTV strains tested [55, 62].  598 
Cross-serotype nAb reactions were also detected here using a wider range of polyclonal 599 
rabbit and sheep antisera, mostly between BTV serotypes within the same Seg-2 nucleo- 600 
type [24, 27], many of which mimic relationships observed in earlier studies of cross- 601 
protection between BTV isolates, in sheep vaccination and challenge experiments [37] 602 
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(Figure 4). One-way reactions were also detected here between viruses or proteins as- 603 
signed to different nucleotypes, indicating the presence of more widely ‘conserved’ neu- 604 
tralising epitopes,  605 
 606 
 607 
Figure 4: Antigenic relationships between BTV serotypes: The BTV serotype antigenic map, originally 608 
developed by Erasmus (1990) [35] to summarise relationships between BTV serotypes, has been modified to 609 
include two-way cross-reactions in SNT, detected here with the rabbit anti rVP2 sera (in red) and sheep 610 
reference-antisera (in blue). A strong, two-way cross-reaction is shown by a thick black connecting line in the 611 
original map, weak reactions by a thin black connecting line and very weak reactions by a dotted black 612 
connecting line. The novel BTV serotypes BTV-25, -26 and -27 are included as nucleotype K (red box). The red 613 
arrows indicate one-way reactions by rabbit anti-rVP2 sera with BTV-26. Several other one way cross-reactions 614 
were also detected in the current study with the rabbit or sheep sera but are not shown in this figure..  615 
 616 
Variations observed in the overall specificities and titres of bAbs and nAbs, between the 617 
rabbit and sheep antisera against individual BTV strains / rVP2 proteins, may in part 618 
reflect differences in the immune mechanisms and responses by different mammalian 619 
species [57]. However, the rabbits were vaccinated with the expressed and non-infectious 620 
VP2 proteins. More cross-reactive epitopes may have been exposed in these individual 621 
proteins, that could be shielded in whole virus (e.g. by interactions with VP5 and VP7).  622 
10 









5 9 12 22 
















Two-way cross-reactive (sheep) 
Two-way cross-reactive (rabbit) 
Viruses 2021, 13, x FOR PEER REVIEW 19 of 34 
 
 
In contrast, the sheep experienced a full BTV infection, presenting VP2 along with the 623 
other viral proteins, as part of an intact and replicating virus. The nAb responses to in- 624 
fection could be influenced by VP2 interactions with the other BTV structural proteins 625 
(particularly VP5 and VP7) in the virus capsid. The smaller BTV outer-capsid protein, has 626 
been shown to influence the overall specificity of nAbs and consequently BTV serotype, 627 
although there is little evidence for direct binding of nAbs to VP5 [4, 22, 34, 36, 54, 63-65].  628 
BTV infection of cellular components of the sheep immune system, and the resulting leu- 629 
copoenia, may also help to refine the nAb response to infection, enhancing serotype spec- 630 
ificity [66].  631 
Large differences were observed in the titres of bAbs or nAbs detected in rabbit and sheep 632 
antisera against the homologous viruses or BTV-rVP2 proteins. This suggests that there 633 
could also be significant differences in both the magnitude and possibly the cross-reac- 634 
tivity between serotypes, in responses by individual sheep or rabbits to the same anti- 635 
gens. These variations could be further explored in a larger study involving infection of 636 
multiple animals with each virus, and vaccinations of multiple animals with the same 637 
rVP2 protein.  638 
4.2: Multidimensional mapping of antigenic relationships  639 
Using antigenic-cartography to compare antibody cross-reactions and titres, provides an 640 
advanced visual model, in some ways similar to the serological-relationship map 641 
developed by Erasmus (1990) [35] (Figure 4). Three-dimensional antigenic maps can help 642 
to identify relationships that could be missed by simple analyses of antibody titres [67, 643 
68]. The 3D maps shown here indicate a broad range of cross-reactivities within and 644 
between BTV serotypes and nucleotypes, clustering the VP2 proteins of all BTV serotypes 645 
in one large group, reflecting their common evolutionary origin as well as similar 646 
structural and functional roles. The nAB reactions in SNT were more highly serotype- 647 
specific than the bAb in I-ELISA, with less cross-reactivity (particularly using the post- 648 
infection sheep antisera) implying that the interactions within the sub-set of neutralising 649 
antibodies are less complex. 650 
The relative positions of individual strains from different serotypes and nucleotypes in 651 
the 3-D maps, could help to inform development of serotyping assays. The relationships 652 
detected in SNT could help to predict or select different VP2 proteins or BTV strains for 653 
development of polyvalent vaccines [69]. Previous phylogenetic analyses of nucleotide 654 
or amino acid sequences of Seg-2 / VP2 have provided valuable information concerning 655 
the evolution and relationships of BTV strains belonging to different topotypes, serotypes 656 
and nucleotypes [24]. Ultimately, variations in the antigenicity of different BTV strains 657 
are the result of accumulated mutations in Seg-2 and reassortment of genome segments 658 
between strains (genetic drift and shift), although not all mutations will alter the 659 
antigenic properties of the individual proteins or virus. Consequently, there is only a 660 
partial correlation between sequence variation in Seg-2 and the specificity of the bAbs 661 
and nAbs generated. Indeed, the antigenic comparisons and analyses described here 662 
show that differences in the amino acid sequence of VP2 between serotypes do not 663 
always correlate closely with changes in the overall antigenicity of VP2, as illustrated by 664 
the 3D maps.  665 
The differences in sequences and antigenicity between different VP2 topotypes within 666 
the same BTV serotype can affect the nAb titres detected. This suggests that the 667 
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accumulation of mutations and differences resulting in antigenic drift between VP2 668 
topotypes within the same serotype but from different geographic origins may be an 669 
important step in the emergence of new and distinct BTV serotypes.  670 
Predictions of antigenic sites based on hydrophobicity analyses indicate that neutralising 671 
epitopes may be located towards the amino external-tip domain predicted for VP2 of 672 
BTV-1, which is considered likely to be exposed towards the outer surface of the virus 673 
particle [70]. This region of VP2, which was not resolved in structural predictions, is also 674 
thought to contain neutralising epitopes [36, 62]. Previous studies have indicated that 675 
VP2 of the insect transmitted orbiviruses have evolved by concatemerisation (duplication) 676 
of a smaller cell-attachment protein, as seen in the tick-borne orbiviruses [71]. 677 
Phylogenetic analyses of the two separate halves of VP2, generated trees with some 678 
obvious differences (Figure S2). The potential for reaction of non-neutralising antibodies 679 
with the carboxy terminal half of VP2 might help to explain the wider cross reactions 680 
detected by ELISA, that do not mimic the cross reactions detected by SNT. 681 
A reaction was detected in both directions using the rabbit anti-rVP2 sera between BTV- 682 
26 and -27, weaker reactions were also detected between BTV-25 and BTV-27, supporting 683 
the grouping of all three ‘novel’ serotypes in nucleotype K (Figures 1 and 4). 684 
Unfortunately, an isolate of BTV-25 that will grow in cell-culture was not available 685 
during this study. It was therefore only possible to explore one-way reactions and the 686 
ability of anti-BTV-25 sera to neutralise different BTV serotypes (but not vice versa). An 687 
update to the serological map originally developed by Erasmus (1990), is shown in Figure 688 
4, illustrating additional two-way relationships that were detected using the expressed 689 
rVP2 proteins and rabbit antisera. A relationship was detected between nucleotypes A 690 
and K in SNT using the rabbit antisera (Figure 2B), indicated by one-way cross reactions 691 
with the novel serotypes (25, 26 and 27) in figure 4, which may have some evolutionary 692 
significance [35]. Several other one-way cross-reactions were also observed in SNT (See 693 
tables 3 and 5) most of which also mimic relationships detected between nucleotypes by 694 
Erasmus [35] but for clarity these are not shown in Figure 4.  695 
Broadly cross-reactive nAbs have previously been detected after sequential vaccina- 696 
tion/infection of sheep with modified live vaccines from two different BTV serotypes 697 
(BTV-3 and -4) and these were significantly enhanced (and at an accelerated rate) follow- 698 
ing challenge with a third heterotypic serotype (BTV-6) [72]. The production of cross- 699 
reactive nAbs, even at low titres, could potentially prime an enhanced secondary im- 700 
mune response to infection by other heterologous strains (anamnestic immune response), 701 
resulting in faster nAb proliferation and greater protection. It may therefore be possible 702 
to elicit a broader cross-serotype neutralizing and protective response by combining 703 
rVP2 subunits from multiple BTV serotypes as part of simultaneous or sequential vac- 704 
cinations. A multivalent and sequential vaccination strategy with multiple ‘live’ BTV 705 
serotypes was previously used in South Africa [73, 74]. The rVP2 proteins described here 706 
represent potential subunit vaccine components, removing any risk of incomplete atten- 707 
uation or subsequent reassortment with field strains associated with modified live virus 708 
vaccines.  709 
The rVP2 proteins of BTV-4 and BTV-8 were previously shown to raise serotype-specific 710 
protective immune responses in IFNAR (-/-) mice, thought to reflect generation of sero- 711 
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type-specific nAbs [23]. However, a significant cross-reactive but non-protective bAb re- 712 
sponse was also detected in the vaccinated mice. The nAb responses detected here 713 
against a wider range of heterologous strains / serotypes in SNT may also be cross-pro- 714 
tective. Although the cross-reactive bAb responses detected in I-ELISA may be largely 715 
non-protective, they could play a role in induction of antibody-dependent cellular cyto- 716 
toxicity and/or opsonisation [75]. However, the existence of non-neutralising antibodies 717 
also raises the possibility of antibody-dependent enhancement (ADE) of infection that 718 
could facilitate early dissemination of infection within the mammalian host [76].   719 
The detection of multiple cross-serotype bAb responses suggests that it would be difficult 720 
to develop serotype-specific ELISA to identify individual BTV serotypes [58, 77].  How- 721 
ever, greater serotype-specificity might be possible by expressing a sub-set of serotype- 722 
specific VP2 epitopes, rather than the whole VP2 proteins, or by using serotype-specific 723 
monoclonal antibodies in a competition ELISA format [78, 79]. 724 
 725 
5. Conclusions 726 
BTV-rVP2 proteins can be rapidly and efficiently synthesised in plants from multiple 727 
BTV strains. This has made it possible to evaluate immune responses to VP2 in the 728 
absence of the other viral proteins, to explore the complex antigenic relationships that 729 
exist between multiple different BTV topotypes, serotypes and nucleotypes. The plant- 730 
expressed rVP2 proteins raised nAbs in rabbits, although these tended to be at lower 731 
titres than in the sheep reference antisera. However, the VP2-bAb response in rabbits was 732 
at higher titres and was more cross-reactive than in the sheep reference. The results 733 
presented here could be usefully extended and enhanced using of a more complete panel 734 
of proteins and antisera, representing additional BTV serotypes and their topotypes, as 735 
well as multiple animals for each virus / VP2 antigen .   736 
A larger study might also identify sufficient cross-serotype reactions that would support 737 
meaningful antigenic cartography of the nAb responses detected in SNT. However, this 738 
technique does provide a quick and easy method to visualise and interpret antigenic 739 
relationships between VP2 proteins which were detected as complex bAb cross-reactions 740 
in I-ELISA between different BTV strains. The results presented here provide a useful 741 
insight into strain cross-reactivity, which may be relevant to vaccine design and 742 
serological assay development [45].   743 
    744 
Author Contributions:   745 
Conceptualization, Petra C. Fay, Peter P. C. Mertens, Houssam Attoui, Sushila Maan and 746 
David Haig; Data curation, Petra C. Fay, Peter P. C. Mertens; Formal analysis, Petra C. 747 
Fay, Peter P. C. Mertens, Fauziah Mohd Jaafar, Houssam Attoui, Elizabeth Reid, Daniel 748 
Horton, Sushila Maan and David Haig; Funding acquisition, Peter P. C. Mertens and 749 
George Lomonossoff; Investigation, Petra Fay, Carrie Batten, Keith Saunders and Peter 750 
P. C. Mertens; Methodology, Petra C. Fay, Keith Saunders, George Lomonossoff and Pe- 751 
ter P. C. Mertens; Project administration, Petra C. Fay, Janet Daly and Peter P. C. 752 
Mertens; Resources, Carrie Batten, Keith Saunders, George Lomonossoff and David 753 
Haig; Software, Petra C. Fay, Fauziah Mohd Jaafar, Houssam Attoui, Daniel Horton, 754 
Sushila Maan; Supervision, Fauziah Mohd Jaafar, George Lomonossoff, Daniel Horton, 755 
David Haig, Janet Daly and Peter P. C. Mertens; Visualization, Petra C. Fay, Fauziah 756 
Mohd Jaafar, Houssam Attoui, Elizabeth Reid, Daniel Horton, David Haig and Peter P. 757 
Viruses 2021, 13, x FOR PEER REVIEW 22 of 34 
 
 
C. Mertens; Writing – original draft, Petra C. Fay, Elizabeth Reid, David Haig and Peter 758 
P. C. Mertens; Writing – review & editing, Petra C. Fay, Houssam Attoui, George Lo- 759 
monossoff, Elizabeth Reid, Daniel Horton, David Haig, Janet Daly and Peter P. C. 760 
Mertens.   761 
Funding: This research was funded by a BBSRC studentship, grant number 762 
BBS/E/I/00001877 and by EU consortium grant “PALE-Blu” grant number 727393. At the 763 
John Innes Centre the work was funded by the BBSRC Institute Strategic Programme 764 
Grant “Molecules from Nature—Enhanced Research Capacity” (BBS/E/J/000PR9794), 765 
and the John Innes Foundation. 766 
 767 
Conflicts of Interest: G.P.L. declares that he is a named inventor on granted patent WO 768 
29087391 A1 which describes the HyperTrans expression system and the pEAQ vectors 769 
used in this manuscript. The other authors declare no conflict of interest. The funders 770 
had no role in the design of the study; in the collection, analyses, or interpretation of 771 





Appendix A 777 
 778 
Supplementary data: The following are available online at www.mdpi.com/xxx/s1,  779 
Figure S1: Neighbour-joining phylogenetic tree for the carboxy and amino terminal 780 
halves of BTV VP2 781 
Table S1, Antigenic map optimisation outputs for rabbit anti-BTV-rVP2 and sheep anti- 782 
BTV reference-sera by I-ELISA and SNT. 783 
Tables S2, Antigenic distance (units) calculated from I-ELISA data, for expressed rVP2 784 
proteins, using rabbit anti-rVP2 sera  785 
Table S3, Antigenic distance (antigenic units) calculated from I-ELISA data for expressed 786 
rVP2 proteins, using sheep anti-BTV reference-sera  787 
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Figure S1 (supplementary): Neighbour-joining phylogenetic trees for the carboxy and amino terminal halves of 804 
BTV VP2 805 
A neighbour-joining phylogenetic tree constructed with aa sequences of VP2(OC1) of BTV-1 to BTV-27 depicting 806 
phylogenetic groupings.  The N-terminal domain of the VP2 (aa 1-480, relative to VP2 sequence of BTV-1/RSArrrr/01: 807 
AJ585122) is shown on the left part of the figure, while the C-terminal domain of the VP2 (aa 481-961, relative to VP2 808 
sequence of BTV-1/RSArrrr/01: AJ585122) is shown on the right.  The trees were generated using the p-distance 809 
algorithm (pairwise deletion) implemented in the MEGA X software programme.  The arrows indicate the relative 810 
positions of the different VP2 nuceotype groups in the two trees. Neither sub-domain tree is identical to that 811 
constructed for the whole protein sequence (Figure 1).  812 
K 
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Table S1 (supplementary): Table S1, Antigenic map optimisation outputs for rabbit anti-BTV-rVP2 and sheep anti- 813 
BTV reference-sera by I-ELISA and SNT. 814 
Map 
Dimensions 
Rabbit anti-BTV-rVP2 sera Sheep anti-BTV reference-sera 

































2D 202.7745 0.82 1.6698 0.99 191.6525 0.83 6.0857 0.99 
3D 174.1195 0.87 1.6698 0.99 159.7894 0.88 6.0857 0.99 
4D 173.2870 0.87 1.6698 0.99 151.5304 0.89 6.0857 0.99 
5D 173.1036 0.88 1.6698 0.99 149.1482 0.90 6.0857 0.99 
  Maps were optimised 500 times each.  815 
 816 
Table S1: Endpoint I-ELISA and SNT titres for the rabbit anti-BTV-rVP2 and sheep post BTV-infection sera were mod- 817 
elled using the ACMACS software (https://acmacs-wieb.antigenic-cartography.org/) to determine optimum map 818 
dimensions that best represent the antigenic relationships observed. Optimised map dimensions that generated 819 
the lowest sum-squared error and the highest table vs map distance correlation coefficient (r2) were selected for 820 
analysis (indicative of optimal map positioning achieved for each data point). On this basis 3D maps were selected 821 
to best represent the multidimensional nature of the antigenic relationships between the different serotypes.   822 
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Table S2 (Supplementary): Antigenic distance (units) calculated from I-ELISA data, for expressed rVP2 823 
proteins, using rabbit anti-rVP2 sera 824 
BTV  α-rVP2 AU bAb titre  BTV  α-rVP2 AU bAb titre  BTV α-rVP2 AU bAb titre  BTV  α-rVP2 AU bAb titre 
1W 
S1w 0 40960  
4E 
S1w 5 1280  
14w 
S6w 0 5120  16w S27 1 5120 
S1e 1 20480  S4w 3 5120  S8w 5 1280  
16e 
S1w 5 1280 
S4w 0 40960  S6w 1 2560  S11w 4 2560  S4w 7 320 
S6w 1 2560  S8w 7 320  S14w 0 40960  S6w 0 5120 
S8w 6 640  S11w 2 10240  S25 1 2560  S8w 6 640 
S11w 2 10240  S14w 7 320  S26 2 2560  S11w 3 5120 
S14w 5 1280  S25 0 5120  S27 0 102403  S14w 5 1280 
S25 2 1280  S26 1 5120  
8w 
S6w 3 640  S25 2 1280 
S26 3 1280  S27 0 10240  S8w 0 40960  S26 2 2560 
S27 2 2560  
10w 
S1w 5 1280  S11w 8 160  S27 2 2560 
1E 
S1w 0 40960  S4w 4 2560  S27 6 160  
25 
S1w 9 80 
S1e 0 40960  S6w 1 2560  
9w 
S1w 5 1280  S4w 6 640 
S4w 7 320  S8w 5 1280  S4w 5 1280  S6w 1 2560 
S6w 0 5120  S11w 4 2560  S6w 1 2560  S8w 10 40 
S8w 5 1280  S14w 7 320  S8w 7 320  S11w 5 1280 
S11w 5 1280  S25 1 2560  S11w 4 2560  S25 3 640 
S25 3 640  S26 2 2560  S14w 7 320  S26 4 640 
S26 4 640  S27 0 10240  S25 1 2560  S27 1 5120 
S27 2 2560  
11w 
S1w 5 1280  S26 2 2560  
26 
S1w 4 2560 
2W 
S1w 2 10240  S4w 1 20480  S27 0 10240  S1e 10 40 
S4w 9 80  S6w 2 1280  
9e 
S1w 4 2560  S4w 3 5120 
S6w 5 160  S8w 8 160  S4w 3 5120  S6w 0 5120 
S8w 10 40  S11w 0 40960  S6w 0 5120  S8w 4 2560 
S11w 5 1280  S14w 6 640  S8w 4 2560  S11w 2 10240 
S14w 10 40  S25 2 1280  S11w 3 5120  S14w 5 1280 
S25 7 40  S26 2 2560  S14w 6 640  S25 1 2560 
S26 8 40  S27 0 10240  S25 1 2560  S26 1 5120 
S27 4 640  
6w 
S1w 6 640  S26 1 5120  S27 0 10240 
4W 
S1w 5 1280  S4w 6 640  S27 1 5120  
27 
S1w 4 2560 
S4w 0 40960  S6w 1 2560  
16w 
S1w 5 1280  S4w 4 2560 
S6w 1 2560  S8w 8 160  S4w 5 1280  S6w 0 5120 
S8w 5 1280  S11w 5 1280  S6w 0 5120  S8w 5 1280 
S11w 0 40960  S14w 8 160  S8w 6 640  S11w 3 5120 
S14w 4 2560  S25 4 320  S11w 4 2560  S14w 5 1280 
S25 2 1280  S26 5 320  S14w 7 320  S25 1 2560 
S26 2 2560  S27 2 2560  S25 1 2560  S26 0 10240 
S27 1 5120  14w S1w 2 10240  S26 1 5120  S27 0 10240 
825 
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Table S2 (Supplementary): Shows the antigenic distances for the rabbit anti-rVP2 sera, calculated from I-ELISA data 826 
using the expressed rVP2 proteins as target antigens.  The expressed VP2 proteins were derived using sequence data 827 
from more recent BTV strains from Europe, the Mediterranean reagion and other selected geographic locations (distinct 828 
topotypes) and the anti-rVP2 sera generated were therefore derived the same strains of BTV. Text colour coding matches 829 
the coding used for different nucleotypes in figures 2, 3 and 4 and table S2 to S5. 830 
  831 
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Table S3 (Supplementary): Antigenic distance (antigenic units) calculated from I-ELISA data for expressed rVP2 proteins, 832 
using sheep anti-BTV reference-sera 833 
BTV  Ref sera AU bAb titre 
 
BTV  Ref sera AU bAb titre 
 
BTV Ref sera AU bAb titre 
 
BTV  Ref sera AU bAb titre 
1W 
S1W 0 5120 
4w 
 
S9w 4 640 
6w 
S1W 7 40 
9w 
S16e 6 40 
S2W 10 10 S11w 2 80 S2W 0 10240 S17w 3 40 
S5W 5 10 S16e 3 329 S3W 0 80 S17w 0 80 
S6W 0 5120 S17w 0 320 S5W 0 320 S19w 0 320 
S10W 4 320 S18w 3 10 S6W 8 20 S20e 6 30 
S16e 6 40 S19w 5 10 S8w 2 640 S21e 0 40 
S17w 4 20 S20e 0 1280 S10w 1 2560 S23e 0 160 
S20e 7 10 S21e 2 10 S11w 0 320 S24w 0 160 
1E 
S1W 2 1280 S22w 0 10 S12w 1 40 S26e 0 1280 
S2W 6 160 S24w 1 80 S16e 3 320 
9e 
S2W 8 40 
S3W 2 20 
4E 
 
S2W 8 40 S17w 2 80 S5W 2 80 
S5W 1 160 S5W 3 40 S19w 3 40 S8w 6 40 
S6W 9 10 S8w 7 20 S20e 4 80 S9w 0 10240 
S8w 6 40 S10w 4 320 
14w 
S2W 6 160 S10w 2 1280 
S10w 2 1280 S11w 4 20 S5W 2 80 S11w 4 20 
S11w 3 40 S13w 0 10 S10w 5 160 S12w 0 80 
S12w 2 20 S16e 6 40 S11w 5 10 S13w 0 10 
S13w 0 10 S17w 2 80 S14w 0 1280 S16e 6 40 
S16e 5 80 S19w 5 10 S15w 0 160 S17w 3 40 
S17w 3 40 S20e 6 20 S17w 2 80 S20e 6 20 
S19w 4 20 
10w 
S2W 6 160 S21e 0 40 S21e 2 10 
S20e 5 40 S5W 1 160 
8w 
S2W 7 80 
16w 
S2W 7 80 
S21e 2 10 S8w 5 80 S5W 2 80 S5W 4 20 
S24w 4 10 S10w 2 1280 S8w 0 2560 S8w 4 160 
S26e 7 10 S11w 1 160 S10w 2 1280 S10w 4 320 
2W 
S2W 0 10240 S16e 3 320 S11w 3 40 S16e 4 160 
S5W 4 20 S17w 0 320 S16e 4 160 S17w  1             160 
S10w 2 1280 S19w 2 80 S17w 4 20 S20e 6 20 
S16e 6 40 S20e 4 80 S19w 4 20 
16 e  
S2w  8 40 
S17w 1 160 S26e 5 40 S20e 5 40 S5W 1 160 
S19w 5 10 
11w 
S2W 9 20 
9w 
S2W 9 20 S8w 3 320 
S20w 5 40 S5W 4 20 S5W 3 40 S10w 0 5120 
4w 
S2W 7 80 S10w 4 320 S8w 7 20 S16e 0 2560 
S3w 3 10 S11w 3 40 S9w 1 5120 S17w 0 320 
S4w 0 10240 S16e 6 40 S10w 3 640 S20e 5 40 
S5w 2 80 S17w 3 40 S11w 5 10     
S8w 5 80 S19w 4 20 S12w 1 40     




Table S3 (Supplementary) - continued: Antigenic distance (antigenic units) calculated from I- 835 


















AU bAb titre 
25 
S2W 6 160 
26 
S2W 6 160 
27 
S2W 9 20 
S3W 2 20 S5W 2 80 S5W 4 20 
S5W 0 320 S8w 5 80 S10w 4 320 
S8w 2 640 S10w 2 1280 S11w 4 20 
S10w 3 640 S11w 5 10 S16e 6 40 
S11w 2 80 S16e 6 40 S17w 2 80 
S12w 0 80 S17w 4 20 S18w 3 10 
S16e 5 80 S19w 5 10 S19w 4 20 
S17w 2 80 S20e 6 20 S20e 5 40 
S19w 4 20 S26e 7 10 S21e 1 20 
S20e 6 20 
 
S23e 4 10 
 S24w 4 10 
 837 
Table S3 (Supplementary): Shows the antigenic distances for the sheep reference antisera, calculated 838 
from I-ELISA data using the rVP2 proteins.  The expressed VP2 proteins were not derived from the 839 
same reference strains of BTV but were generated using sequence data from more recent BTV strains 840 
from Europe, the Mediterraneam reagion and other selected geographic locations (distinct 841 
topotypes). Text colour coding matches the coding used for different nucleotypes in figures 2, 3 and 842 
4 and table S2 to S5.  843 
 844 
 845 
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